These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34997322)

  • 1. Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case.
    Cambier A; Dossier C; Hogan J; Baudouin V; Maisin A; Couderc A; Kwon T; Gleeson PJ; Monteiro RC
    Pediatr Nephrol; 2022 Jul; 37(7):1597-1603. PubMed ID: 34997322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
    Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
    Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.
    Cambier A; Gleeson PJ; Abbad L; Canesi F; da Silva J; Bex-Coudrat J; Deschênes G; Boyer O; Rabant M; Ulinski T; Hogan J; Peuchmaur M; Berthelot L; Monteiro RC
    Kidney Int; 2022 Feb; 101(2):274-287. PubMed ID: 34756952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
    Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
    PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
    Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
    J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors.
    Berthelot L; Papista C; Maciel TT; Biarnes-Pelicot M; Tissandie E; Wang PH; Tamouza H; Jamin A; Bex-Coudrat J; Gestin A; Boumediene A; Arcos-Fajardo M; England P; Pillebout E; Walker F; Daugas E; Vrtosvnik F; Flamant M; Benhamou M; Cogné M; Moura IC; Monteiro RC
    J Exp Med; 2012 Apr; 209(4):793-806. PubMed ID: 22451718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.
    Papista C; Lechner S; Ben Mkaddem S; LeStang MB; Abbad L; Bex-Coudrat J; Pillebout E; Chemouny JM; Jablonski M; Flamant M; Daugas E; Vrtovsnik F; Yiangou M; Berthelot L; Monteiro RC
    Kidney Int; 2015 Aug; 88(2):276-85. PubMed ID: 25807036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
    He JW; Cui DF; Zhou XJ; Chen P; Li Y; Zhang X; Wang YN; Gan T; Liu LJ; Shi SF; Zhu L; Hou P; Lv JC; Zhang H
    Front Immunol; 2022; 13():846323. PubMed ID: 35359934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy.
    Jhee JH; Kang HY; Wu M; Nam BY; Chang TI; Jung SY; Park S; Kim H; Yun HR; Kee YK; Yoon CY; Park JT; Yoo TH; Kang SW; Han SH
    Clin Chem Lab Med; 2017 Nov; 56(1):75-85. PubMed ID: 28672768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
    Reily C; Moldoveanu Z; Pramparo T; Hall S; Huang ZQ; Rice T; Novak L; Komers R; Jenkinson CP; Novak J
    Am J Physiol Renal Physiol; 2024 May; 326(5):F862-F875. PubMed ID: 38511222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
    Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
    PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
    Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
    PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
    J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy.
    Vuong MT; Hahn-Zoric M; Lundberg S; Gunnarsson I; van Kooten C; Wramner L; Seddighzadeh M; Fernström A; Hanson LÅ; Do LT; Jacobson SH; Padyukov L
    Kidney Int; 2010 Dec; 78(12):1281-7. PubMed ID: 20811333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA
    Chiu YL; Lin WC; Shu KH; Fang YW; Chang FC; Chou YH; Wu CF; Chiang WC; Lin SL; Chen YM; Wu MS
    Front Immunol; 2021; 12():638309. PubMed ID: 34177889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
    J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy.
    Suzuki Y; Matsuzaki K; Suzuki H; Okazaki K; Yanagawa H; Ieiri N; Sato M; Sato T; Taguma Y; Matsuoka J; Horikoshi S; Novak J; Hotta O; Tomino Y
    Clin Exp Nephrol; 2014 Oct; 18(5):770-7. PubMed ID: 24477513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
    Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
    PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
    PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.